Briacell Therapeutics Corp experiences a notable surge in stock price this week.
Briacell Therapeutics Corp (BCT.TO) has seen significant movement in its stock price recently, with a 7.93% increase on Tuesday and a remarkable 22.64% rise over the past week. This uptick comes amidst the company's strategic efforts to enhance its market presence.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$48.54M
52W high
$27.20
52W low
$3.68
1W change
+6.60%
Beta
1.54
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 275.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+275.2% Upside
Current Price
C$5.33
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
64.8%
Annualized
90-Day Vol
87.4%
Annualized
Trend (90d)
-43.4%
Annualized drift
90d Mean
C$4.56
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.06 | C$4.05 – C$6.33 |
| 60 trading days | C$4.81 | C$3.50 – C$6.59 |
| 90 trading days | C$4.56 | C$3.10 – C$6.72 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should take note of Briacell's recent stock performance and its ongoing initiatives, which may signal positive developments for the company's future prospects.
Briacell's Stock Rises 22.64% This Week
The stock's recent performance marks a stark contrast to its year-to-date decline of 43.18%, highlighting volatility and potential investor interest.
Bull case
Briacell's engagement of consulting and branding firms shows a proactive strategy for market access and commercialization. This approach could lead to future growth opportunities for the company.
Bear case
Despite the recent price increase, the stock is still significantly below its 200-day moving average. This suggests there may be underlying challenges that investors should keep in mind.
Price Action
Briacell Therapeutics Corp's stock closed at C$5.33 on Tuesday, reflecting a significant 7.93% increase for the day. Over the past week, the stock has surged by 22.64%, indicating a growing interest among investors.
Company News
On July 7, 2026, Briacell Therapeutics announced the engagement of consulting and branding firms aimed at supporting the commercial and market access evaluation of its product, Bria-IMT™. This strategic move is intended to enhance the company's market presence and facilitate growth.
Technical Picture
BCT.TO is currently trading above its 50-day moving average of C$4.78, representing an 11.6% increase. However, it remains significantly below its 200-day moving average of C$8.78, indicating a 39.3% decline from that benchmark. The stock's 52-week range has been between C$3.68 and C$27.20, with the current price at only 7% of that range. With a beta of 1.54, the stock exhibits higher volatility compared to the broader market.
Advertisement
